Page last updated: 2024-08-23

lovastatin and Attention Deficit Disorder with Hyperactivity

lovastatin has been researched along with Attention Deficit Disorder with Hyperactivity in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ackerson, JD; Acosta, MT; Armstrong, CL; Barton, B; Byars, AW; Cantor, A; Cantor, NL; Cutter, G; Fisher, M; Gioia, GA; Gutmann, DH; Hearps, SJ; Hunter, SJ; Isenberg, J; Klesse, L; Korf, B; North, KN; O'Neil, SH; Packer, RJ; Payne, JM; Rey-Casserly, C; Rosser, T; Schorry, E; Silva, AJ; Stavinoha, PL; Tonsgard, J; Ullrich, NJ; Viskochil, D; Walsh, KS; Wolters, PL	1
Brown, RA; Cannon, TD; Cui, Y; Frankland, PW; Jentsch, JD; Kushner, SA; Li, W; Silva, AJ	1
Acosta, MT	1

Trials

1 trial(s) available for lovastatin and Attention Deficit Disorder with Hyperactivity

Article	Year
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology, 2016, Dec-13, Volume: 87, Issue:24 Topics: Attention; Attention Deficit Disorder with Hyperactivity; Double-Blind Method; Executive Function; Female; Humans; Learning; Lovastatin; Male; Neurofibromatosis 1; Neuropsychological Tests; Quality of Life	2016

Other Studies

2 other study(ies) available for lovastatin and Attention Deficit Disorder with Hyperactivity

Article	Year
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Current biology : CB, 2005, Nov-08, Volume: 15, Issue:21 Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Blotting, Western; Excitatory Postsynaptic Potentials; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Learning Disabilities; Long-Term Potentiation; Lovastatin; Maze Learning; Mice; Mice, Mutant Strains; Mitogen-Activated Protein Kinases; Neurofibromatosis 1; Proto-Oncogene Proteins p21(ras)	2005
[The neurobiology of learning difficulties: neurofibromatosis type 1 as a model for researching and treating learning disorders]. Revista de neurologia, 2007, Mar-02, Volume: 44 Suppl 2 Topics: Anticholesteremic Agents; Attention Deficit Disorder with Hyperactivity; Brain; Cognition Disorders; Humans; Learning Disabilities; Lovastatin; Neurofibromatosis 1; Neurofibromin 1	2007

Article

Year

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.

Current biology : CB, 2005, Nov-08, Volume: 15, Issue:21

Topics: Analysis of Variance; Animals; Attention Deficit Disorder with Hyperactivity; Blotting, Western; Excitatory Postsynaptic Potentials; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Learning Disabilities; Long-Term Potentiation; Lovastatin; Maze Learning; Mice; Mice, Mutant Strains; Mitogen-Activated Protein Kinases; Neurofibromatosis 1; Proto-Oncogene Proteins p21(ras)

2005

[The neurobiology of learning difficulties: neurofibromatosis type 1 as a model for researching and treating learning disorders].

Revista de neurologia, 2007, Mar-02, Volume: 44 Suppl 2

Topics: Anticholesteremic Agents; Attention Deficit Disorder with Hyperactivity; Brain; Cognition Disorders; Humans; Learning Disabilities; Lovastatin; Neurofibromatosis 1; Neurofibromin 1

2007